Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.

被引：4

作者：

McGregor, Bradley Alexander

Balar, Arjun Vasant

Rosenberg, Jonathan E.

Van der Heijden, Michiel Simon

Park, Se Hoon

Lee, Jae-Lyun

Kojima, Takahiro

Harrison, Michael Roger

Heath, Elisabeth I.

Stein, Mark N.

Loriot, Yohann

Necchi, Andrea

Steinberg, Joyce Leta

Liang, Shang-Ying

Trowbridge, Janet

Petrylak, Daniel P.

Yu, Evan Y.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Weill Cornell Med Coll, New York, NY USA

[5] Netherlands Canc Inst, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands

[6] Samsung Med Ctr, Seoul, South Korea

[7] Asan Med Ctr, Seoul, South Korea

[8] Univ Ulsan, Coll Med, Seoul, South Korea

[9] Univ Tsukuba, Tsukuba, Ibaraki, Japan

[10] Duke Univ, Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA

[11] Wayne State Univ, Sch Med, Dept Oncol, Karmanos Canc Inst, Detroit, MI USA

[12] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

[13] Univ Paris Saclay, Gustave Roussy, Dept Canc Med, Villejuif, France

[14] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[15] Astellas, Northbrook, IL USA

[16] Seagen Inc, Bothell, WA USA

[17] Yale Canc Ctr, New Haven, CT USA

[18] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[19] Univ Washington, Seattle, WA 98195 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4524

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4524

引用

页数：3